NexVita Technology Corp.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
The core technology of NexVita Technology Corp. is the patented K-sensor. The function of the K-sensor is to accurately detect Korotkoff sounds in the artery, meeting medical-grade requirements while remaining free from environmental noise interference. It can eliminate 99% of ambient noise, ensuring it is unaffected even in 90-decibel environments. During every blood pressure measurement, the K-sensor simultaneously collects dynamic arterial data to provide deep cardiovascular insights.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2018
Unified Business No.
42966996
Status
Active
Number of Employees
0
Total Paid-in
Capital
95,828,600 (NT$)
Location of Company
Taiwan
, Taoyuan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
NexVita Technology Corp. was established in June 2018 and has secured NT$95.82 million in capital through four angel funding rounds. Currently, it has nine employees, primarily consisting of R&D personnel. The three co-founders of NexVita Technology Corp. are Kun-Yi Lin, Pei-Yuan Tsai, and Dr. Chi-Cheng Chien. The company received investment from the National Development Fund in 2019 and won the 20th National Innovation Award in 2023. From 2022 to 2023, clinical validation was conducted at National Cheng Kung University Hospital, comparing results with nurse auscultation on 198 cardiovascular patients, which demonstrated outstanding efficacy. An international paper is currently being written. The NEX300 fully automatic Korotkoff sound blood pressure monitor is expected to undergo clinical trials between 2025 and 2026 (with the Q-submission already completed with the US FDA).
(The content above was translated by AI.)
(The content above was translated by AI.)
